Clyde Thornsberry
Overview
Explore the profile of Clyde Thornsberry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thornsberry C, Brown N, Draghi D, Evangelista A, Yee Y, Sahm D
Postgrad Med
. 2008 Oct;
120(3 Suppl 1):32-8.
PMID: 18931469
Infections caused by multidrug-resistant (MDR) Streptococcus pneumoniae remain a major concern when selecting an appropriate antimicrobial agent. In this analysis, 27 781 isolates of S pneumoniae collected from 2001 to...
2.
Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective
Sahm D, Brown N, Thornsberry C, Jones M
Postgrad Med
. 2008 Oct;
120(3 Suppl 1):16-24.
PMID: 18931467
Antimicrobial resistance by common respiratory tract pathogens remains a global concern, but surveillance programs allow us to recognize trends in susceptibility that may help guide empiric antimicrobial selection. During 2003...
3.
Sahm D, Brown N, Draghi D, Evangelista A, Yee Y, Thornsberry C
Postgrad Med
. 2008 Oct;
120(3 Suppl 1):8-15.
PMID: 18931466
Antimicrobial resistance observed among common respiratory tract pathogens--Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis--may complicate empiric therapeutic selection to treat community-acquired respiratory tract infections. The Tracking Resistance in the United...
4.
Draghi D, Benton B, Krause K, Thornsberry C, Pillar C, Sahm D
Antimicrob Agents Chemother
. 2008 Apr;
52(7):2383-8.
PMID: 18443115
Telavancin is an investigational, rapidly bactericidal lipoglycopeptide antibiotic that is being developed to treat serious infections caused by gram-positive bacteria. A baseline prospective surveillance study was conducted to assess telavancin...
5.
Draghi D, Benton B, Krause K, Thornsberry C, Pillar C, Sahm D
J Antimicrob Chemother
. 2008 Apr;
62(1):116-21.
PMID: 18424792
Objectives: Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide...
6.
Sahm D, Benninger M, Evangelista A, Yee Y, Thornsberry C, Brown N
Otolaryngol Head Neck Surg
. 2007 Feb;
136(3):385-9.
PMID: 17321864
Objective: To test the susceptibility of Streptococcus pneumoniae sinus isolates collected across the United States against commonly used antimicrobial agents. Study Design And Setting: S. pneumoniae sinus isolates (N =...
7.
Karlowsky J, Jones M, Thornsberry C, Evangelista A, Yee Y, Sahm D
Clin Infect Dis
. 2005 Feb;
40 Suppl 2:S89-98.
PMID: 15712102
From 2001 to 2003, rates of susceptibility to piperacillin-tazobactam (86%), ceftazidime (80%), ciprofloxacin (68%), and levofloxacin (67%) did not decrease or decreased by <1.5%, whereas the rate of susceptibility to...
8.
Jones M, Draghi D, Thornsberry C, Karlowsky J, Sahm D, Wenzel R
Ann Clin Microbiol Antimicrob
. 2004 Jul;
3:14.
PMID: 15283864
Background: Globally ICUs are encountering emergence and spread of antibiotic-resistant pathogens and for some pathogens there are few therapeutic options available. Methods: Antibiotic in vitro susceptibility data of predominant ICU...
9.
Flamm R, Weaver M, Thornsberry C, Jones M, Karlowsky J, Sahm D
Antimicrob Agents Chemother
. 2004 Jun;
48(7):2431-6.
PMID: 15215091
For the period from 1999 to 2002 in the United States, the in vitro susceptibilities of 52,637 Pseudomonas aeruginosa isolates to 10 antimicrobial agents were evaluated. The isolates were from...
10.
Jones M, Karlowsky J, Draghi D, Thornsberry C, Sahm D, Nathwani D
Int J Antimicrob Agents
. 2004 May;
23(3):240-6.
PMID: 15164964
Bone infections, which can be acute or chronic, often require aggressive antibiotic therapy, whether treated at home or in the community. Surveillance programmes are essential tools in the monitoring of...